Evaluating the short-term effect of Fampridine on cognitive function in Multiple sclerosis patients
Phase 3
Recruiting
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT20161212031362N4
- Lead Sponsor
- Iranian Center of Neurological Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 108
Inclusion Criteria
Definite MS diagnosis according to McDonald 2017 criteria
Age between 18-60 years
SDMT score below the 20th percentile of normative values
Exclusion Criteria
History of relapse within 2 months
History of seizure/epilepsy
History of major depression or psychosis
Reluctance to enroll in the study
Moderate or higher renal dysfunction (eGFR=< 50mL/min/1.73m2)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Fampridine's cognitive effects in multiple sclerosis patients?
How does Fampridine compare to standard-of-care treatments for cognitive impairment in multiple sclerosis?
Which biomarkers correlate with Fampridine response in IRCT20161212031362N4 MS trial?
What adverse events are associated with Fampridine use in MS patients and how are they managed?
Are there combination therapies involving Fampridine that enhance cognitive outcomes in multiple sclerosis?